INTRODUCTION: This study compared two atomoxetine titration dosing schedules and two atomoxetine maintenance doses for treating adolescent attention-deficit/hyperactivity disorder (ADHD) inattention and hyperactivity/impulsivity. METHODS: Adolescents (N = 267) were randomized to a slow or fast titration schedule. Patients who responded continued on a 40-week maintenance treatment, randomized to either 0.8 or 1.4 mg/kg/day. RESULTS: During the acute period, significant benefit was demonstrated with both titration schedules on the ADHD Rating Scale total score. Although patients in both groups maintained benefit relative to week 0, statistically significant loss of benefit was found for patients maintained on 0.8 mg/kg/day but not on 1.4 mg/kg/day. A similar pattern was observed on the Clinical Global Impressions-ADHD-Severity scores and Life Participation Scale for ADHD-Child Version scores. Mean grades for most subjects improved for patients in both maintenance treatment groups although most improvements were not statistically significant. CONCLUSIONS: In adolescents with ADHD, treatment benefit at 8 weeks was better maintained long-term with 1.4 mg/kg/day than with 0.8 mg/kg/day. Improvement in adaptive functioning and age-appropriate developmental function was also demonstrated. Atomoxetine 0.8 and 1.4 mg/kg/day were equally well tolerated. CLINICAL TRIALS REGISTRY: Maintenance of benefit with atomoxetine hydrochloride in adolescents with ADHD, NCT00191035.
RCT Entities:
INTRODUCTION: This study compared two atomoxetine titration dosing schedules and two atomoxetine maintenance doses for treating adolescent attention-deficit/hyperactivity disorder (ADHD) inattention and hyperactivity/impulsivity. METHODS: Adolescents (N = 267) were randomized to a slow or fast titration schedule. Patients who responded continued on a 40-week maintenance treatment, randomized to either 0.8 or 1.4 mg/kg/day. RESULTS: During the acute period, significant benefit was demonstrated with both titration schedules on the ADHD Rating Scale total score. Although patients in both groups maintained benefit relative to week 0, statistically significant loss of benefit was found for patients maintained on 0.8 mg/kg/day but not on 1.4 mg/kg/day. A similar pattern was observed on the Clinical Global Impressions-ADHD-Severity scores and Life Participation Scale for ADHD-Child Version scores. Mean grades for most subjects improved for patients in both maintenance treatment groups although most improvements were not statistically significant. CONCLUSIONS: In adolescents with ADHD, treatment benefit at 8 weeks was better maintained long-term with 1.4 mg/kg/day than with 0.8 mg/kg/day. Improvement in adaptive functioning and age-appropriate developmental function was also demonstrated. Atomoxetine 0.8 and 1.4 mg/kg/day were equally well tolerated. CLINICAL TRIALS REGISTRY: Maintenance of benefit with atomoxetine hydrochloride in adolescents with ADHD, NCT00191035.
Authors: Yi Lu; Arvid Sjölander; Martin Cederlöf; Brian M D'Onofrio; Catarina Almqvist; Henrik Larsson; Paul Lichtenstein Journal: JAMA Psychiatry Date: 2017-08-01 Impact factor: 21.596
Authors: Nicola C Savill; Jan K Buitelaar; Ernie Anand; Kathleen Ann Day; Tamás Treuer; Himanshu P Upadhyaya; David Coghill Journal: CNS Drugs Date: 2015-02 Impact factor: 5.749
Authors: Angelo Camporeale; Kathleen Ann Day; Dustin Ruff; Jody Arsenault; David Williams; Douglas K Kelsey Journal: Drug Saf Date: 2013-08 Impact factor: 5.606
Authors: Kevin M Antshel; Teresa M Hargrave; Mihai Simonescu; Prashant Kaul; Kaitlin Hendricks; Stephen V Faraone Journal: BMC Med Date: 2011-06-10 Impact factor: 8.775